New Zealand's Living Cell Technologies Closer To Getting Pigs To Market
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Auckland-based cell implant company Living Cell Technologies has started working on an animal-derived therapeutics project with the New Zealand government's investment promotion agency, Investment New Zealand
You may also be interested in...
New Zealand Living Cell-Otsuka Partnership Implants Pig Cells Into Parkinson’s Patient
New Zealand’s Living Cell Technologies has taken a key clinical step in regenerative and replacement branded cell therapy work focused on Parkinson’s disease and type 1 diabetes that has drawn investment from Japan’s Otsuka.
New Zealand Living Cell-Otsuka Partnership Implants Pig Cells Into Parkinson’s Patient: AusBiotech
New Zealand’s Living Cell Technologies has taken a key clinical step in regenerative and replacement branded cell therapy work focused on Parkinson’s disease and type 1 diabetes that has drawn investment from Japan’s Otsuka. The progress report was presented at the Australia Biotech Invest conference in Melbourne in late October.
New Zealand's Living Cell Technologies Cleared For Phase II Diabetes Trials As Pig Herd Becomes More Famous
PERTH, Australia - Auckland-based Living Cell Technologies received the green light from New Zealand regulators to proceed with Phase II clinical trials of its lead product Diabecell, based on encapsulated pig insulin-producing cells aimed at normalizing blood glucose levels for people with type 1 diabetes